.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,637,699

« Back to Dashboard

Details for Patent: 5,637,699

Title: Process for preparing morpholine tachykinin receptor antagonists
Abstract:Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
Inventor(s): Dorn; Conrad P. (Plainfield, NJ), Hale; Jeffrey J. (Westfield, NJ), Finke; Paul E. (Milltown, NJ), MacCoss; Malcolm (Freehold, NJ), Mills; Sander G. (Woodbridge, NJ), Shah; Shrenik K. (Metuchen, NJ), Chambers; Mark S. (Watford Harts, GB2), Harrison; Timothy (Great Dunmow, GB2), Ladduwahetty; Tamara (Buckhurst Hill, GB2), Williams; Brian J. (Great Dunnow, GB2)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Filing Date:May 22, 1995
Application Number:08/445,489
Claims:1. A process for the preparation of a compound of structural formula XI: ##STR12## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is selected from the group consisting of:

(1) hydrogen;

(2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl-C.sub.1-3 alkoxy,

(e) phenyl,

(f) --CN,

(g) halo,

(h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are independently selected from:

(i) hydrogen,

(ii) C.sub.1-6 alkyl,

(iii) hydroxy-C.sub.1-6 alkyl, and

(iv) phenyl,

(i) --NR.sup.9 COR.sup.10,

(j) --NR.sup.9 CO.sub.2 R.sup.10,

(k) --CONR.sup.9 R.sup.10,

(l) --COR.sup.9,

(m) --CO.sub.2 R.sup.9 ;

(n) heterocycle, wherein the heterocycle is selected from the group consisting of:

(A) benzimidazolyl,

(B) benzofuranyl,

(C) benzothiophenyl,

(D) benzoxazolyl,

(E) furanyl,

(F) imidazolyl,

(G) indolyl,

(H) isooxazolyl,

(I) isothiazolyl,

(J) oxadiazolyl,

(K) oxazolyl,

(L) pyrazinyl,

(M) pyrazolyl,

(N) pyridyl,

(O) pyrimidyl,

(P) pyrrolyl,

(Q) quinolyl,

(R) tetrazolyl,

(S) thiadiazolyl,

(T) thiazolyl,

(U) thienyl,

(V) triazolyl,

(W) azetidinyl,

(X) 1,4-dioxanyl,

(Y) hexahydroazepinyl,

(Z) piperazinyl,

(AA) piperidinyl,

(AB) pyrrolidinyl,

(AC) tetrahydrofuranyl, and

(AD) tetrahydrothienyl,

and wherein the heterocycle is unsubstimted or substituted with one or more substituent(s) selected from:

(i) C.sub.1-6 alkyl, unsubstimted or substituted with halo, --CF.sub.3, --OCH.sub.3, or phenyl,

(ii) C.sub.1-6 alkoxy,

(iii) oxo,

(iv) hydroxy,

(v) thioxo,

(vi) --SR.sup.9, wherein R.sup.9 is as defined above,

(vii) halo,

(viii) cyano,

(ix) phenyl,

(x) trifluoromethyl,

(xi) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m is 0, 1 or 2,

(xii) --NR.sup.9 COR.sup.10,

(xiii) --CONR.sup.9 R.sup.10,

(xiv) --CO.sub.2 R.sup.9, wherein R.sup.9 is as defined above, and

(xv) --(CH.sub.2).sub.m --OR.sup.9 ;

(3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl-C.sub.1-3 alkoxy,

(e) phenyl,

(f) --CN,

(g) halo,

(h) --CONR.sup.9 R.sup.10,

(i) --COR.sup.9,

(j) --CO.sub.2 R.sup.9,

(k) heterocycle;

(4) C.sub.2-6 alkynyl;

(5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) C.sub.1-6 alkoxy,

(c) C.sub.1-6 alkyl,

(d) C.sub.2-5 alkenyl,

(e) halo,

(f) --CN,

(g) --NO.sub.2,

(h) --CF.sub.3,

(i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10

(j) --NR.sup.9 COR.sup.10,

(k) --NR.sup.9 CO.sub.2 R.sup.10,

(l) --CONR.sup.9 R.sup.10,

(m) --CO.sub.2 NR.sup.9 R.sup.10,

(n) --COR.sup.9,

(o) --CO.sub.2 R.sup.9 ;

R.sup.2 and R.sup.3 are independently selected from the group consisting of:

(1) hydrogen,

(2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl-C.sub.1-3 alkoxy,

(e) phenyl,

(f) --CN,

(g) halo,

(h) --NR.sup.9 R.sup.10,

(i) --NR.sup.9 COR.sup.10,

(j) --NR.sup.9 CO.sub.2 R.sup.10,

(k) --CONR.sup.9 R.sup.10,

(l) --COR.sup.9, and

(m) --CO.sub.2 R.sup.9 ;

(3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl-C.sub.1-3 alkoxy,

(e) phenyl,

(f) --CN,

(g) halo,

(h) --CONR.sup.9 R.sup.10,

(i) --COR.sup.9,

(j) --CO.sub.2 R.sup.9 ;

(4) C.sub.2-6 alkynyl;

(5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) C.sub.1-6 alkoxy,

(c) C.sub.1-6 alkyl,

(d) C.sub.2-5 alkenyl,

(e) halo,

(f) --CN,

(g) --NO.sub.2,

(h) --CF.sub.3,

(i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10,

(j) --NR.sup.9 COR.sup.10,

(k) --NR.sup.9 CO.sub.2 R.sup.10,

(l) --CONR.sup.9 R.sup.10,

(m) --CO.sub.2 NR.sup.9 R.sup.10,

(n) --COR.sup.9,

(o) --CO.sub.2 R.sup.9 ;

and the groups R.sup.1 and R.sup.2 may be joined together to form a heterocyclic ring selected from the group consisting of:

(a) pyrrolidinyl,

(b) piperidinyl,

(c) pyrrolyl,

(d) pyridinyl,

(e) imidazolyl,

(f) oxazolyl, and

(g) thiazolyl,

and wherein the heterocyclic ring is unsubstituted or substituted with one or more substituent(s) selected from:

(i) C.sub.1-6 alkyl,

(ii) oxo,

(iii) C.sub.1-6 alkoxy,

(iv) --NR.sup.9 R.sup.10,

(v) halo, and

(vi) trifluoromethyl;

and the groups R.sup.2 and R.sup.3 may be joined together to form a carbocyclic ring selected from the group consisting of:

(a) cyclopentyl,

(b) cyclohexyl,

(c) phenyl,

and wherein the carbocyclic ring is unsubstituted or substituted with one or more substituents selected from:

(i) C.sub.1-6 alkyl,

(ii) C.sub.1-6 alkoxy,

(iii) --NR.sup.9 R.sup.10,

(iv) halo, and

(v) trifluoromethyl;

and the groups R.sup.2 and R.sup.3 may be joined together to form a heterocyclic ring selected from the group consisting of:

(a) pyrrolidinyl,

(b) piperidinyl,

(c) pyrrolyl,

(d) pyridinyl,

(e) imidazolyl,

(f) furanyl,

(g) oxazolyl,

(h) thienyl, and

(i) thiazolyl,

and wherein the heterocyclic ring is unsubstituted or substituted with one or more substituent(s) selected from:

(i) C.sub.1-6 alkyl,

(ii) oxo,

(iii) C.sub.1-6 alkoxy,

(iv) --NR.sup.9 R.sup.10,

(v) halo, and

(vi) trifluoromethyl;

R.sup.6, R.sup.7 and R.sup.8 are independently selected from the group consisting of:

(1) hydrogen;

(2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl-C.sub.1-3 alkoxy,

(e) phenyl,

(f) --CN,

(g) halo,

(h) --NR.sup.9 R.sup.10,

(i) --NR.sup.9 COR.sup.10,

(j) --NR.sup.9 CO.sub.2 R.sup.10,

(k) --CONR.sup.9 R.sup.10,

(l) --COR.sup.9, and

(m) --CO.sub.2 R.sup.9 ;

(3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) oxo,

(c) C.sub.1-6 alkoxy,

(d) phenyl-C.sub.1-3 alkoxy,

(e) phenyl,

(f) --CN,

(g) halo,

(h) --CONR.sup.9 R.sup.10,

(i) --COR.sup.9,

(j) --CO.sub.2 R.sup.9 ;

(4) C.sub.2-6 alkynyl;

(5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from:

(a) hydroxy,

(b) C.sub.1-6 alkoxy,

(c) C.sub.1-6 alkyl,

(d) C.sub.2-5 alkenyl,

(e) halo,

(f) --CN,

(g) --NO.sub.2,

(h) --CF.sub.3,

(i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10,

(j) --NR.sup.9 COR.sup.10,

(k) --NR.sup.9 CO.sub.2 R.sup.10,

(l) --CONR.sup.9 R.sup.10,

(m) --CO.sub.2 NR.sup.9 R.sup.10,

(n) --COR.sup.9,

(o) --CO.sub.2 R.sup.9 ;

(6) halo,

(7) --CN,

(8) --CF.sub.3,

(9) --NO.sub.2,

(10) --SR.sup.14, wherein R.sup.14 is hydrogen or C.sub.1-6 alkyl,

(11) --SOR.sup.14,

(12) --SO.sub.2 R.sup.14,

(13) NR.sup.9 COR.sup.10,

(14) CONR.sup.9 COR.sup.10,

(15) NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10,

(16) NR.sup.9 CO.sub.2 R.sup.10, wherein R.sup.9 and R.sup.10 e,

(17) hydroxy,

(18) C.sub.1-6 alkoxy,

(19) COR.sup.9,

(20) CO.sub.2 R.sup.9,

(21) 2-pyridyl,

(22) 3-pyridyl,

(23) 4-pyridyl,

(24) 5-tetrazolyl,

(25) 2-oxazolyl, and

(26) 2-thiazolyl;

R.sup.11, R.sup.12 and R.sup.13 are independently selected from the definitions of R.sup.6, R.sup.7 and R.sup.8 ;

Z is C.sub.1-6 alkyl;

which comprises: contacting a compound of formula IX: ##STR13## with a hydride reducing agent selected from a group consisting of: diisobutylaluminum hydride: lithium tri(sec-butyl)borohydride: and lithium aluminum hydride; in an organic solvent at low temperature; followed by acylation of the resultant alcohol/alkoxide with a substituted benzoyl halide, substituted benzoic anhydride, substituted benzoic mixed anhydride or substituted activated benzoate ester, in which the phenyl ring of the acylating agent is substituted with R.sup.6, R.sup.7, and R.sup.8, in an organic solvent at low temperature for a sufficient time to produce a compound of structural formula X: ##STR14## and subsequently contacting the compound of formula X with a titanium ylide (generated from a reagent selected from the group consisting of: .mu.-chloro-.mu.-methylene-(bis(cyclopentadienyl)titanium)dimethyl-amlumin um; and dimethyl titanocene; or the reagent prepared by the reduction of a 1,1-dibromoalkane with zinc and titanium tetrachloride in the presence of N,N,N',N'-tetramethylethylenediamine) to afford an enol ether which is then hydrogenated in the presence of a a catalyst selected from palladium on carbon, platinum on carbon, and rhodium on carbon to afford the compound of formula XI.

2. A process for preparing 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phen yl-4-(3-(5-oxo-1,2,4-triazolo)methyl-morpholine which comprises:

contacting 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phen yl morpholine with N-methyl-carboxy-2-chloro-acetamidrazone to give an N-methylcarboxy-2-chloro-acetamidrazone derivative,

followed by heating the resultant N-methylcarboxy-2-chloro-acetamidrazone derivative in xylenes at reflux to give 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)pheny l-4-(3-(5-oxo-1,2,4-triazolo)methyl-morpholine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc